Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,475 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Demyelinating Disorders Clear all
Recruiting No phase listed Observational

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

NCT05966467
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 2:56 PM EDT
Completed No phase listed Observational

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

NCT05334472
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Kesimpta
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 23, 2026, 2:56 PM EDT
Not listed Not applicable Interventional

The Effect of Motor Imagery on Balance in Persons With Multiple Sclerosis

NCT05615207
View directory record Official record
Conditions
Falls, Motor Imagery, Multiple Sclerosis, Balance, Fatigue
Interventions
Motor Imagery as compared to physical practice for balance tasks
Other
Lead sponsor
Dominican University New York
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 23, 2026, 2:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions
TRX319, Bendamustine
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Kansas City, Kansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis

NCT03345199
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Inspiratory Muscle Trainer (IMT)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 23, 2026, 2:56 PM EDT
Recruiting No phase listed Observational

Complementary and Alternative Care in Multiple Sclerosis

NCT01703429
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

NCT01626092
View directory record Official record
Conditions
Lysosomal Storage Disease, Peroxisomal Disorder
Interventions
Campath-1H, Clofarabine, Melphalan, Total Body Irradiation with Marrow Boosting, Hematopoietic stem cell transplantation, Cyclosporine A, Mycophenolate mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 23, 2026, 2:56 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Task Specific Home Exercise Program

NCT06486116
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Task Specific Physical Therapy Home Program
Behavioral
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 23, 2026, 2:56 PM EDT
Recruiting No phase listed Observational

Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

NCT06516458
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis, Relapsing-Remitting
Interventions
Camera Based Kinematic Analysis
Diagnostic Test
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

NCT00176592
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Betaseron, Copaxone
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Early Phase 1 Interventional

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

NCT04781309
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
NT-I7
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jul 23, 2026, 2:56 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 2:56 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01028209
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
Interventions
[18F] PBR06
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis

NCT03423121
View directory record Official record
Conditions
Progressive Multiple Sclerosis
Interventions
Tauroursodeoxycholic Acid, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 23, 2026, 2:56 PM EDT
Completed No phase listed Observational

Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response

NCT03316404
View directory record Official record
Conditions
Multiple Sclerosis, MS
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

NCT02201849
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Study Drug, Active Control, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jul 23, 2026, 2:56 PM EDT
Recruiting Phase 1 Interventional

Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)

NCT06150716
View directory record Official record
Conditions
Pelizaeus-Merzbacher Disease
Interventions
ION356
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 23, 2026, 2:56 PM EDT
Terminated Not applicable Interventional

Exercise in Multiple Sclerosis

NCT02716701
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Exercise Group, Control Group, wristband activity tracker
Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Adherence in Pediatric Multiple Sclerosis

NCT02234713
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Motivational Interview, Video Attention Control
Behavioral · Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
10 Years to 18 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Birmingham, Alabama • Loma Linda, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis

NCT05888727
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Seated Physical activity INtervention for persons with MS, "SPIN" program- Intervention Condition, WEllness for Longevity Living with MS (WELL)- Control Condition
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 23, 2026, 2:56 PM EDT
Active, not recruiting Not applicable Interventional

TRAIN-BW: Backward Walking Training in Multiple Sclerosis

NCT04091464
View directory record Official record
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic, Accidental Fall
Interventions
Backward Walking Training, Forward Walking Training
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 23, 2026, 2:56 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

NCT03759522
View directory record Official record
Conditions
Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
Interventions
DPA-714 PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 23, 2026, 2:56 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)

NCT01730131
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
2 Years to 120 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 2:56 PM EDT